This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutNimenrix Dosing and AdministrationNimenrix in the Green BookNimenrix TravelSupport & ResourcesSupport & ResourcesClinic Support MaterialsVideosMaterials

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.
Adverse event reporting information can be found at the bottom of the page.

Nimenrix in the Green Book

Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.1

Nimenrix is one of several vaccines that are referenced in the Green Book for MenACWY vaccination.2 

Invasive meningococcal disease

Invasive meningococcal disease (IMD) is primarily associated with meningitis and septicaemia which can be fatal or have long-term consequences, even with appropriate medical care.3,4 

Up to 10% of patients who contract invasive meningococcal disease die.5Up to 20% of survivors suffer severe long-term consequences6Long-term consequences may include3:Limb AmputationSkin ScarringVision or Hearing ImpairmentMental or Motor Skill ImpairmentCertain behaviours in specific age groups are associated with an increased risk of invasive meningococcal disease:Adolescents and young adults have the highest asymptomatic carriage rates, with almost 25% of 19-year-olds carrying the bacteria at any one time.7,8 

Social behaviours associated with an increased risk of invasive meningococcal disease in adolescents and young adults include:4,6,7,9KissingSmokingMass Gatherings (eg sporting events or music festivals)Close Living QuartersThe National Immunisation Schedule includes an adolescent meningococcal ACWY conjugate vaccine programme.10 Please refer to the National Immunisation Schedule for the latest guidance on the MenACWY conjugate vaccine programmeGo to the ScheduleLoadingVisit Chapter 22 of the Green Book for more information on meningococcal disease and immunisationGo to the Green BookLoading
ReferencesNimenrix. Summary of Product Characteristics, Great Britain, Pfizer Ltd. Available hereUK Health Security Agency. The Green Book of Immunisation. Chapter 22: Meningococcal. Available here. (Last accessed September 2023)Vyse A, Anonychuk A, Jakel A, et al. The burden and impact of severe and long-term sequelae of Meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597–604.World Health Organization. Meningococcal meningitis, fact sheet. Available here  (last accessed September 2023).Chang Q, Tzeng Y, Stephens D. Meningococcal disease: changes in epidemiology and prevention. Clinical Epidemiology. 2012;4 237–245.Martinón-Torres F. Deciphering the burden of Meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59 (2 suppl):S12–S20.Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission and disease. Expert Rev Vaccines 2016;15(5):641–58.Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61.Muttalif A, Presa, J, Haridy, H et al. Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events. Infect Dis Ther. 2019;8:569–579.UK Health Security Agency. Complete routine immunisation schedule. Available here  (Last accessed September 2023).
PP-NIM-GBR-0402. September 2023
Register to receive personalised marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

Sign up hereLoading
Order Clinic Materials

Help your patients to feel confident about meningococcal disease - access MedISA to order printed clinic support materials to your surgery, pharmacy or other healthcare centre.

 Order materials nowLoading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​